Pharmacogenomics is increasingly moving into mainstream clinical practice. Careful
consideration must be paid to inclusion of diverse populations in research, translation and …

Hypertension is a prevalent public health problem, contributing to> 10 million deaths
annually. Though multiple therapeutics exist, many patients suffer from treatment-resistant …

At the dawn of the new decade, it is judicious to reflect on the boom of knowledge about
polygenic risk for essential hypertension supplied by the wealth of genome-wide association …

Background Reported association between statin use and cataract risk is controversial. The
SLCO1B1 gene encodes a transport protein responsible for statin clearance. The aim of this …

Background Cytochrome P450 family 2 subfamily C member 19 (CYP2C19) is a hepatic
enzyme involved in the metabolism of clopidogrel from a prodrug to its active metabolite …

Pharmacogenomics (PGx) is the intersection of genomic medicine and pharmacology
whereby knowledge of variation in an individual's genome is utilized to inform prescribing …

Abstract Aims The United Kingdom (UK) Prescribing Safety Assessment (PSA) is a 2‐h
online assessment of basic competence to prescribe and supervise the use of medicines. It …

Aims CYP2C19 is a hepatic enzyme involved in the metabolism of antidepressants
associated with increased gastrointestinal bleed (GIB) risk. The aim of our study was to …

Abstract Background South Asian ancestry populations are underrepresented in genomic
studies and therapeutics trials. British South Asians suffer from multi-morbidity leading to …

Multimorbidity, estrogen use, and Factor V Leiden (FVL) are known independent risk factors
for venous thromboembolism (VTE). This cross-sectional analysis of women in the Genes & …